HIV cure study testing a new drug combination
Part of Infections clinical trials.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have HIV-1 subtype B and are being cared for at the Saint-Luc HIV reference center.
- You are currently taking HIV medications (cART) and your viral load is undetectable.
- You do not have chronic hepatitis B or C.
- You are not pregnant and do not have any acute illness or weakened immune system from other treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two or more investigational drugs that can activate the hidden HIV reservoir in your body might help eliminate it. The goal is to see if this approach is safe and could help lead to a cure for HIV.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
This trial tests whether combining immune-boosting drugs with chidamide (a medication that may wake up hidden HIV) can help your body control HIV without daily antiretroviral therapy. It aims to achieve a 'functional cure,' meaning the virus stays suppressed even after stopping regular HIV meds.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.